AR125219A1 - Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo - Google Patents
Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismoInfo
- Publication number
- AR125219A1 AR125219A1 ARP220100720A ARP220100720A AR125219A1 AR 125219 A1 AR125219 A1 AR 125219A1 AR P220100720 A ARP220100720 A AR P220100720A AR P220100720 A ARP220100720 A AR P220100720A AR 125219 A1 AR125219 A1 AR 125219A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acid
- acid sequence
- group
- sequence selected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2021107773A RU2796937C2 (ru) | 2021-03-24 | Моноклональное антитело или его антигенсвязывающий фрагмент, которое специфически связывается с gd2 (ганглиозид gd2), и его применение |
Publications (1)
Publication Number | Publication Date |
---|---|
AR125219A1 true AR125219A1 (es) | 2023-06-28 |
Family
ID=83395963
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP220100720A AR125219A1 (es) | 2021-03-24 | 2022-03-25 | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo |
Country Status (9)
Country | Link |
---|---|
CN (1) | CN117677695A (zh) |
AR (1) | AR125219A1 (zh) |
CL (1) | CL2023002843A1 (zh) |
CO (1) | CO2023012549A2 (zh) |
CR (1) | CR20230456A (zh) |
EC (1) | ECSP23072412A (zh) |
TW (1) | TW202304989A (zh) |
UY (1) | UY39687A (zh) |
WO (1) | WO2022203552A1 (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2330860T3 (es) * | 2004-01-22 | 2009-12-16 | Merck Patent Gmbh | Anticuerpos anticancerosos con fijacion del complemento reducida. |
AU2011268110B2 (en) * | 2010-06-19 | 2016-05-19 | Memorial Sloan-Kettering Cancer Center | Anti-GD2 antibodies |
CN105705165B (zh) * | 2013-03-15 | 2020-04-24 | 纪念斯隆-凯特琳癌症中心 | 高亲和力抗gd2抗体 |
-
2022
- 2022-03-24 CR CR20230456A patent/CR20230456A/es unknown
- 2022-03-24 CN CN202280024459.8A patent/CN117677695A/zh active Pending
- 2022-03-24 WO PCT/RU2022/050096 patent/WO2022203552A1/en active Application Filing
- 2022-03-24 UY UY0001039687A patent/UY39687A/es unknown
- 2022-03-24 TW TW111111114A patent/TW202304989A/zh unknown
- 2022-03-25 AR ARP220100720A patent/AR125219A1/es unknown
-
2023
- 2023-09-22 EC ECSENADI202372412A patent/ECSP23072412A/es unknown
- 2023-09-22 CO CONC2023/0012549A patent/CO2023012549A2/es unknown
- 2023-09-25 CL CL2023002843A patent/CL2023002843A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN117677695A (zh) | 2024-03-08 |
WO2022203552A1 (en) | 2022-09-29 |
ECSP23072412A (es) | 2023-10-31 |
CR20230456A (es) | 2023-12-13 |
TW202304989A (zh) | 2023-02-01 |
UY39687A (es) | 2022-08-31 |
CO2023012549A2 (es) | 2023-10-09 |
CL2023002843A1 (es) | 2024-03-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR126019A1 (es) | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
PE20181952A1 (es) | Anticuerpos anti-ll-33, composiciones, metodos y usos de los mismos | |
BR112020015479A2 (pt) | Anticorpos anticlaudina 18.2 e usos dos mesmos | |
FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
RU2019118359A (ru) | Антитело к cd73 человека | |
US20220332816A1 (en) | Anti-tigit antibodies | |
AR110101A1 (es) | Miembros de unión (2) | |
JP2020529863A (ja) | 抗ror1抗体とその作製及び使用方法 | |
JP2012518425A5 (zh) | ||
PE20191079A1 (es) | Inmunoglobulinas y usos de estas | |
PE20210554A1 (es) | Anticuerpos anti-cxcr5 y composiciones y usos de los mismos | |
AR123480A1 (es) | Moléculas de unión terapéuticas | |
PE20231080A1 (es) | Anticuerpos que se unen a cd3 y cd19 | |
PE20230464A1 (es) | Union de anticuerpos multiespecificos a bcma | |
AR124084A1 (es) | ANTICUERPOS DE CADENA PESADA QUE SE UNEN AL RECEPTOR a DE FOLATO | |
RU2019134462A (ru) | Антитела, связывающиеся с steap-1 | |
AR125219A1 (es) | Anticuerpo monoclonal o fragmento de unión al antígeno del mismo que se une específicamente al gd2 (gangliósido gd2), y uso del mismo | |
US20210371514A1 (en) | Materials and methods for treating stress-related disorders and cancer | |
AR125040A1 (es) | Constructos anti-vista y usos de estos | |
AR127271A1 (es) | Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos | |
PE20240895A1 (es) | Anticuerpos del receptor antitransferrina y usos de los mismos | |
US20210317216A1 (en) | Anti-flt3 antibodies and compositions | |
CA3216468A1 (en) | Vhh polypeptides that bind to interleukin 6 (il-6), compositions and methods of use thereof |